Healius (ASX:HLS) Moat Score: 5/10 (As of Jun. 27, 2026)


ASX:HLS Healius Ltd ASX:HLS
53 GF Score
Price A$0.37
GF Value A$1.01
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Healius Moat Score?

Healius ASX:HLS +1.39% 53 Moat Score is 5 as of Jun. 27, 2026. GuruFocus rates ASX:HLS with a GF Score™ of 53/100 and a GF Value™ of A$1.01 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Healius ranks better than 87.56% on this metric.

Healius has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Healius has Narrow Moat: Healius Ltd has a solid narrow moat due to its strong distribution network and significant regulatory barriers in the healthcare sector. While it has some pricing power and customer loyalty, it does not possess a wide moat due to competitive pressures and limited innovation.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Healius might have Narrow Moat - Solid narrow moat.

Healius  (ASX:HLS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Healius Moat Score Related Terms

ASX:HLS vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Healius's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Healius Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Healius's Moat Score distribution charts can be found below:

* The bar in red indicates where Healius's Moat Score falls into.


ASX:HLS
53GF Score
Healius Ltd ASX:HLS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Healius (ASX:HLS) has a Moat Score of 5 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Healius ranks #27 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 12.4%.
Is Healius' Moat Score too high?
Healius' current Moat Score is 5. Based on the distribution chart, Healius ranks #27 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Healius has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Healius' Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Healius ranks #27 out of 217 companies for Moat Score. This places Healius in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Healius's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healius stock overvalued right now?
Based on GuruFocus' analysis, Healius (ASX:HLS) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.01, compared to a current price of A$0.37 — trading 63.9% below its estimated fair value. The current Moat Score is 5. Healius' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Healius (ASX:HLS), the current Moat Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.37 is trading 63.9% below its estimated GF Value™ of A$1.01. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

  • Moat Score: 5
  • GF Value™: A$1.01 vs. price of A$0.37 (63.9% below fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Other Exchanges PGZ:Germany
Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
53GF Score

Get the complete analysis for ASX:HLS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.37
Price
A$1.01
GF Value